AstraZeneca

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

COVID-19 Monthly Newsletter Service - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Publishing, Health, FDA, COVID-19, Communications, Clinical Trials, MHLW, CSL, Abivax, AstraZeneca, Partnership, University, Ageing, EUL, Arcturus Therapeutics, UNICEF, Bharat Biotech, Ministry of Health, XBB, Messenger, Laboratory, World Health Organization, OTC, Therapy, Johnson & Johnson, Vaccination, Rapid antigen test, Phase II, WHO, CSL Limited, Ministry, Vaccine, Marketing, Fulcrum, UN, Pharmaceutical industry

The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "COVID-19 Monthly Snapshot" newsletter has been added to ResearchAndMarkets.com's offering.
  • In November 2023, 64 investigational drugs were active in Phase 3 of clinical development.
  • Globally, the overall confirmed cases of COVID-19 reached more than 772 million as of November 22, 2023.
  • Fifty-eight COVID-19 vaccines were evaluated in Phase 3, 40 in Phase 2, 84 in Phase 1, and 199 in pre-clinical stages.

US Digital Marketing Trends in Non-small Cell Lung Cancer: Merck's Keytruda.com Achieved the Highest Total Traffic Across NSCLC Patient Websites - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Health, Oncology, AstraZeneca, Pfizer, Digital, Comparison, Patient, Roche, Social media, Merck, BMS, Lung cancer, DDA, HCP, Pharmaceutical industry

Merck's Keytruda.com achieved the highest total traffic across non-small cell lung cancer (NSCLC) patient sites in the US, with over 2.4 million visitors from October 2022 to September 2023.

Key Points: 
  • Merck's Keytruda.com achieved the highest total traffic across non-small cell lung cancer (NSCLC) patient sites in the US, with over 2.4 million visitors from October 2022 to September 2023.
  • Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.
  • AstraZeneca's Imfinzihcp.com achieved the highest total traffic across NSCLC HCP sites in the US, with almost 300,000 visitors from October 2022 to September 2023.
  • Overall, the highest proportion of traffic to branded NSCLC websites for HCPs originated from direct sources, followed by paid and organic traffic.

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
Professional Services, Health, Other Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Partner, PTHR1, AstraZeneca, Disease, Acromegaly, Patient, Lead, Acquisition, Endocrine disease, Cooley LLP, Investment, Series, Centerview Partners, Alexion, Endocrinology, Hypoparathyroidism

We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.

Key Points: 
  • We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • “Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca.
  • Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Vanguard Renewables Celebrates a Decade of Clean Energy Innovation

Retrieved on: 
Wednesday, March 13, 2024
Agriculture, Natural Resources, Environment, Alternative Energy, Energy, Food, Beverage, Green Technology, Retail, Dairy Farmers of America, Natural gas, Farm, Manure, AstraZeneca, University, Incineration, Science, Recycling, Partnership, Vanguard, Carbon, Eye, Host, Workforce, Starbucks, Engineering, RNG, Digestion, Renewable energy

Vanguard Renewables®, a farm-based provider of organic material solutions for the food and beverage industry, is celebrating a decade in clean energy innovation and organic materials solutions.

Key Points: 
  • Vanguard Renewables®, a farm-based provider of organic material solutions for the food and beverage industry, is celebrating a decade in clean energy innovation and organic materials solutions.
  • As part of its aggressive growth strategy, Vanguard Renewables is developing multiple Farm Powered® digesters across the country that will service almost every major metropolitan market.
  • “When we launched Vanguard Renewables in 2014, I was researching why something that had been so successful in Europe had not been replicated in the United States,” stated John Hanselman, Chief Strategy Officer at Vanguard Renewables.
  • With a team of dedicated solutions providers, world-class scientists and engineers, strong leadership, and dedicated institutional partners Vanguard Renewables is well-positioned to drive the adoption of renewable energy solutions across the country for the next decade and beyond.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, March 13, 2024
Health, Biotechnology, Research, AstraZeneca, Patient, EDT, Sale, G&A, Therapy, ATM, PV, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights.
  • “2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic,” said Craig Tooman, President and CEO of Silence.
  • In addition to zerlasiran, we’ve made excellent progress advancing divesiran in PV and remain on-track to report phase 1 data by June.
  • “We ended December 2023 with approximately $68.8 million and significantly increased our cash position in early 2024 to over $200 million,” said Rhonda Hellums, Chief Financial Officer of Silence.

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Health, Other Science, Finance, Research, Science, Biotechnology, RAPS, Eli Lilly, AstraZeneca, Ferris State University, Patient, Esperion Therapeutics, Sale, IPO, Pleasure, Esperies, Insys Therapeutics, Therapy, Investment, Multimedia, Pharmaceutical industry

Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.

Key Points: 
  • Sofinnova Investments , a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor.
  • View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
    Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors.
  • Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
  • We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Other Health, Eli Lilly, ICL, Boston Scientific, Growth, AstraZeneca, Presbyopia, Eli Lilly and Company, University, Near-sightedness, Art, Columbia University, Indiana State University, EVO, STAAR, Senior, MBA, Bayer, Campbell University, Nursing credentials and certifications, Marketing, CFA, Waters Corporation, Guidant, Retirement, Arthur Butcher, Economics, Astigmatism, Management

“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.

Key Points: 
  • “Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • "Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction.
  • He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
  • We wish her the best in her future endeavors.”
    With the appointment of Messrs. Butcher and Jiang to the Board, the STAAR Surgical Board is now comprised of eight directors, seven of whom are independent non-employee directors.

EcoVadis Announces 2024 Sustainability Achievement Awards

Retrieved on: 
Monday, March 11, 2024
Supply Chain Management, Professional Services, Environmental, Social and Governance (ESG), Retail, Environment, Sustainability, Green Technology, AstraZeneca, Entrepreneurship, Award, Natural Resources, GHG, Social responsibility, A2A, Water, Cohesion, Leadership Council, Sustainable procurement, Renewable energy

EcoVadis , the leading provider of business sustainability ratings, today announced the winners of its eighth annual Sustainability Achievement Awards (formerly Sustainable Procurement Awards).

Key Points: 
  • EcoVadis , the leading provider of business sustainability ratings, today announced the winners of its eighth annual Sustainability Achievement Awards (formerly Sustainable Procurement Awards).
  • The EcoVadis Sustainability Achievement Awards recognize companies who are leading the charge in engaging and integrating sustainability into their relationships with trading partners around the globe and creating an impact through their sustainability business practices.
  • Our suppliers are now able to develop and report stronger sustainability action plans supported by EcoVadis and we are truly pleased of this recognition.”
    In addition to these three awards, EcoVadis also recognizes a selection of small- and medium-sized rated companies across the globe who achieved exceptionally high performance in their EcoVadis rating in the past year.
  • Learn more on the 2024 Regional Sustainability Leadership Awards here .